Determination of the Contents of Antioxidants and Their Degradation Products in Sodium Chloride Injection for Blood Transfusion

Bo Tao,1,2 Gang Wang,2 Zongning Yin,1 Xiacong Pu,2 Yan Jiang,2 Luohong Zhang,2 Jie Cheng,2 Yong Li,3 and Jiayu Zhang3

1Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, China
2Sichuan Institute for Food and Drug Control, Chengdu 611731, China
3Sichuan Taipingyang Pharmaceutical Co., Ltd., Chengdu 611731, China

Correspondence should be addressed to Zongning Yin; zongningyin@163.com

Received 14 April 2020; Accepted 22 May 2020; Published 22 June 2020

Academic Editor: Antony C. Calokerinos

Copyright © 2020 Bo Tao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The infusion bag is mainly made up of polyolefin polymer. Antioxidants are usually added to these polymer materials in the production process to prevent the materials from aging and enhance the stability of the materials. Because of the potential harm of antioxidants to human body, it is necessary to limit the amount of antioxidants migrating to the pharmaceutical solutions. In the present study, we developed and validated the HPLC method for the simultaneous quantification of antioxidants and their degradation products migrating to sodium chloride solution for injection. A total of six antioxidants and six their degradation products were separated and simultaneously determined by using a Waters Symmetry RP18 column (250 × 4.6 mm, 5 μm) and gradient elution of methanol/acetonitrile/acetic acid-water (1:99, v/v) at a flow rate of 1.0 mL/min. The detection wavelength was set at 277 nm, and the column temperature was maintained at 35°C. The method was validated in terms of limit of detection (LOD, 0.011–0.151 μg/mL), limit of quantification (LOQ, 0.031–0.393 μg/mL), intraday precision (0.25%–3.17%), interday precision (0.47%–3.48%), linearity (0.1–46.8 μg/mL, r > 0.9994), stability (0.35%–3.29%), and accuracy (80.39%–104.31%). In the extraction experiment, antioxidants, BHT, 1010, 1330, 1076, and 168, and their degradation products, 1310 and DBP, were detected in the packaging materials. Only 1310 was detected in the migration experiment. The maximum daily dosage of sodium chloride for blood transfusion is three bags, and the content of 1310 in long-term testing samples is from 0 to 12 months ranging from 37.44 μg/3 bags to 48.71 μg/3 bags. The daily intake of 1310 did not exceed 48.71 μg, which was much lower than its permitted daily exposure (PDE, 300 μg/day). Therefore, the antioxidants and their degradation products migrating into the drug solution would not cause drug safety risks.

1. Introduction

The earliest intravenous infusion container is the feather needle tube and animal bladder invented by Christopher and Robert [1]. Glass bottles have been used as infusion containers for nearly a century since it was invented in 1920. The glass bottle has the advantages of higher transparency, excellent pressure resistance, and good thermal stability. However, the glass bottle packaging is poorly sealed, easy to peel off, fragile [2, 3], and not conducive to transportation and has invisible cracks caused by collision and only sem i-open infusion mode can be used [4]; the rubber plug must come in contact with the liquid medicine directly. All of these factors may cause the contamination of the drug solution. In recent years, glass bottles have gradually been replaced by non-PVC multilayer coextrusion film infusion soft bags [5].

The 0.9% sodium chloride injection for blood transfusion is used together with the Baxter Fenwal CS-3000 plus blood component separator and a single disposable blood
cell separator. About 200 mL sodium chloride injection is used for flushing the air in the pipeline of single disposable blood cell separator before blood collection. After blood collection, about 300 mL sodium chloride injection is used for flushing the residual blood components in the pipeline of single disposable blood cell separator back to the body. Therefore, the dosage of sodium chloride injection is about 500–600 mL each time. The maximum daily dose of sodium chloride injection for blood transfusion is about three bags (250 mL/bags).

Sodium chloride injection for blood transfusion enters the human body by intravenous injection. Therefore, the safety of packaging materials for transfusion is very important. At present, the widely used packaging materials for infusion are non-PVC multilayer coextrusion films prepared by mixing polypropylene and polystyrene-ethylene-butylene-styrene block copolymer (SEBS) with different proportions.

The infusion bag and the packaged product will go through a series of long processes, such as packaging, sterilization, transportation, and shelf display. During processing, storage, and use, they will age due to the influence of light, heat, air, and other factors. The automatic oxidation of polymer is a process consisting of a series of free radical reactions. Adding antioxidants to the polymer can prevent the material from aging, property change, damage, yellowing, and embrittlement, leading to an enhanced stability of the material [6, 7].

The antioxidants commonly used in polymers are mainly divided into hindered phenols and phosphites. Hindered phenolic antioxidants, known as free radical scavengers, contain OH functional groups that can act as H donors to deactivate the free radicals (ROO•), stabilizing the material against photo- and thermal oxidation [8]. Phosphite antioxidants are auxiliary antioxidants, also known as hydroperoxides (ROOH) decomposers. When the hydroperoxides reach a certain concentration, the free radical oxidation reaction will be accelerated. Phosphite antioxidants can decompose the hydroperoxides produced in the oxidation process through changes in its phosphorus atom valence and generation of stable inactive products and play a role in stabilizing the polymer material.

Phosphite ester antioxidants generally have a synergistic effect when used together with hindered phenolic antioxidants to achieve the best antioxidant effect. The most frequently used hindered phenolic antioxidants are BHT, Irganox 3114 (3114), Irganox 1010 (1010), Irganox 1076 (1076), Irganox 1330 (1330), and so on [9–14]. The most frequently used phosphite antioxidant is Irgafos 168 (168). HPLC or HPLC-MS/MS is currently used to detect antioxidants and their degradation products BHT, 3114, 1010, 1330, 1076, and 168 as well as their degradation products BHT-Q, BHT-OH, BHT-CHO, BHT-COOH, 1310, and DBP [19–22], which could simultaneously detect antioxidants and their degradation products rapidly and efficiently. In the extractable migration experiment, the solid-phase extraction (SPE) method was used to concentrate the analytes in the pharmaceutical solution from the packaging materials migrating to the pharmaceutical solution. The relationship between antioxidants and their degradation products is shown in Figure 1.

2. Materials and Methods

2.1. Chemicals and Reagents. Methanol (HPLC grade) and acetonitrile (HPLC grade) were purchased from Fisher Scientific. Deionized water was produced with the Milli-Q® Advantage A10 water purification system (EMD Millipore Corporation). Dichloromethane was obtained from Chengdu Chron Chemicals Co., Ltd. Acetic acid (HAc) was supplied by CNW Technologies. The sources and information of studied antioxidants and their degradation products are presented in Table 1.
2.2. *Instruments and Optimized Chromatographic Conditions for Separation.* Chromatographic separation of antioxidants and their degradation products was performed on the Waters e2695 Separation Modules equipped with a UV detector (monitoring at 277 nm) and an empower 2 data handling system (Waters Corporation, produced in the USA). The analytes were separated on a Waters SymmetryShield™ RP18 column (5 μm, 250 × 4.6 mm) equipped with a security guard cartridge system (Phenomenex) at 35°C. The mobile phase A was acetonitrile, mobile phase B was methanol, and mobile phase C was HAc-water (1:99, v/v). The injection volume was 10 μL. The HPLC system was operated at a flow rate 1.0 mL/min in a gradient mode. The analysis time was about 42 min. The gradient elution program of mobile phase is presented in Table 2.

![Schematic diagram of antioxidant degradation pathways](image)

(a) Hindered phenolic antioxidants and their degradation products

(b) Phosphite antioxidants and their degradation products

**Figure 1:** Schematic diagram of antioxidant degradation pathways. (a) Hindered phenolic antioxidants and their degradation products. The degradation products of BHT, 1310, 1330, and 3114 are mainly BHT-Q, BHT-OH, BHT-CHO, and BHT-COOH, respectively. (2) The degradation products of 1010 and 1076 are mainly 1310. (b) Phosphite antioxidants and their degradation products. The degradation product of 168 is mainly DBP.
2.3. Preparation of Standard and Sample Solutions

2.3.1. Preparation of Standard Solutions. The standard stock solutions of individual antioxidants and their degradation products (BHT-OH, BHT-COOH, 1310, BHT-CHO, DBP, BHT, 3114, 1010, 1330, 1076, and 168) were prepared within a concentration range of 950–1,050 μg/mL in mixture of dichloromethane and methanol (1:4, v/v). These solutions were mixed and diluted by methanol to prepare working standards at a concentration of about 40 μg/mL. The secondary standard solutions were diluted from working standards by methanol. The standards solutions were stored in amber-colored glass volumetric flasks at −20°C.

2.3.2. Extraction of Antioxidants and Their Degradation Products from Packaging Materials. The packaging materials were cut into small particles of about 5 mm × 5 mm, and then 0.5 g of packaging materials was weighed and placed in a microwave digestion tube, followed by an addition of 10 mL dichloromethane. The mixture was allowed to stand overnight (about 12 h), followed by microwave digestion at 40°C for 45 min and then cooled to room temperature. The extract solution was filtered through a glass funnel to remove solid particles and then vacuum-evaporated to remove the dichloromethane. The residue after evaporation was sonicated with 8 mL methanol. The solution was transferred to a 10 mL volumetric flask and diluted with methanol up to the mark. The solution was filtered with 0.45 μm nylon membrane and analyzed by HPLC.

2.3.3. SPE Procedure of Sodium Chloride Injection for Blood Transfusion Samples. The packaged 0.9% sodium chloride solutions for blood transfusion were stored for stability testing at 25 ± 2°C with RH of 40% ± 5% for 12 months, and sampling was performed at 0, 3, 6, and 12 months. SPE was used to concentrate the analytes to improve their detection sensitivity. Before sample loading, SPE cartridges (Chromclean™ HLB 500mg/6mL, 30PK, SWEll) were conditioned with 3 mL methanol, followed by 10 mL deionized water. Subsequently, 50 mL sodium chloride (Nigale, China) was passed through the cartridges at a flow rate of 2 mL/min. The analytes were eluted into 10 mL brown glass volumetric flask using dichloromethane and methanol, and then the methanol was added to the mark of the volumetric flask.

2.4. Development of HPLC Method and Optimization of Chromatographic Conditions. The individual standard stock solutions (antioxidants and their degradation products) were diluted to about 5 μg/mL with methanol, and each standard solution was, respectively, scanned by a UV-visible spectrophotometer (Evolution™ 201, Thermo Scientific) to detect the maximum absorption wavelength.

---

### Table 1: Reagent information.

| Abbreviation | CAS no | Chemical name | Source |
|-------------|--------|---------------|--------|
| BHT-OH      | 88-26-6| 3,5-Di-tert-butyl-4-hydroxybenzyl alcohol | Alfa Aesar (China) Chemicals |
| BHT-COOH    | 1421-49-4| 3,5-Di-tert-butyl-4-hydroxybenzoic acid | Alfa Aesar |
| 1310        | 20170-32-5| 3,5-Di-tert-butyl-4-hydroxyphenylpropionic acid | Alfa Aesar |
| BHT-CHO     | 1620-98-0| 3,5-Di-tert-butyl-4-hydroxybenzaldehyde | Adamas Reagent Co., Ltd. |
| BHT-Q       | 719-22-2| 2,6-Di-tert-butyl-p-benzoquinone | Adamas Reagent Co., Ltd. |
| DBP         | 96-76-4| 2,4-Di-tert-butylphenol | TCI Company |
| BHT         | 128-37-0| 2,6-Di-tert-butyl-4-methylphenol | Dr. EHrenstorfer GmbH |
| 3114        | 27676-62-6| Tris(3,5-di-tert-butyl-4-hydroxybenzyl) isocyanurate | Aladdin |
| 1010        | 6683-19-8| Pentaerythritol tetraakis[(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate) | Sigma-Aldrich |
| 1330        | 1709-70-2| 1,3,5-Trimethyl-2,4,6-tris(3,5-di-tert-butyl-4-hydroxybenzyl)benzene | Sigma-Aldrich |
| 1076        | 2082-79-3| Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate | Sigma-Aldrich |
| 168         | 31570-04-4| Tris(2,4-ditert-butylphenyl) phosphate | TCI Company |

### Table 2: The gradient elution program of mobile phase.

| Time (min) | Mobile phase A (acetonitrile, %) | Mobile phase B (methanol, %) | Mobile phase C (acetic acid-water, %) |
|------------|---------------------------------|-------------------------------|-------------------------------------|
| 0          | 10                              | 50                            | 40                                  |
| 3          | 10                              | 50                            | 40                                  |
| 6          | 20                              | 50                            | 30                                  |
| 9          | 25                              | 50                            | 25                                  |
| 12         | 25                              | 50                            | 25                                  |
| 15         | 30                              | 50                            | 20                                  |
| 19         | 0                               | 90                            | 10                                  |
| 21         | 0                               | 100                           | 0                                   |
| 31         | 0                               | 100                           | 0                                   |
| 32         | 10                              | 50                            | 40                                  |
| 42         | 10                              | 50                            | 40                                  |
Mobile phase C consisting of deionized water and 0.1%, 0.2%, 0.5%, 1.0%, or 1.5% HAc was used to investigate the effects of different HAc contents in mobile phase C on the peak shape.

2.5. System Suitability Testing. System suitability testing is an integral part of liquid chromatography, which is used to verify whether the liquid chromatographic system is adequate for the intended quantitative analysis. United States Pharmacopeia (USP) requires testing for system suitability [23]. System suitability testing was performed by injecting working standard solutions at a concentration of about 40 μg/mL in six replicates. The parameters, including repeatability, tailing factor, resolution, capacity factor, and theoretical plate, were studied.

2.6. Method Validation. The analytical method validation was evaluated by determining the following parameters: limits of detection and quantification (LOD and LOQ), linearity, precision, stability, and accuracy.

2.6.1. LOD, LOQ, and Linearity. The stock solution containing 12 analytes (antioxidants and their degradation products) was diluted to a series of different concentrations and analyzed by HPLC. The calibration curves were constructed by plotting the peak areas versus the corresponding concentrations of each analyte. The linear range was 0–46.8 μg/mL. The LOD and LOQ were calculated from the concentration of each group of analytes with a signal/noise ratio (S/N) at 3 and 10, respectively.

2.6.2. Precision. Precision included intraday and interday precision, which was assessed by relative standard deviation (RSD) of the peak area of the spiked sample [24]. The mixed working standard solutions (250 μL, 500 μL, and 1,250 μL) at a concentration of about 40 μg/mL were added to the 50 mL sodium chloride solution. The spiked samples were processed according to the procedure in Section 2.3.3.

2.6.3. Accuracy. Accuracy was assessed according to the recovery of the spiked sample. The mixed working standard solutions (200 μL, 250 μL, and 300 μL) at a concentration of about 40 μg/mL were added to 50 mL sodium chloride solution. The spiked samples were processed according to the procedure in Section 2.3.3.

2.6.4. Stability. The stability was evaluated based on the RSD of peak area of the spiked samples. The mixed working standard solutions (250 μL, 1,250 μL, and 2,500 μL) at a concentration of about 40 μg/mL were added to 50 mL sodium chloride solution. The spiked samples were processed according to the procedure in Section 2.3.3 and analyzed at 0, 2, 4, 6, 8, 10, 12, 14, 16, 20, and 24 h.

3. Results and Discussion

3.1. Development of HPLC Method. Antioxidants and their degradation products were aromatic compounds with two or three peaks in the UV absorption spectrum. The absorption peaks of antioxidants and their degradation products were about 200 nm close to the far ultraviolet region and 277 nm close to the visible region. Most organic compounds had absorption in the far ultraviolet region. In order to eliminate interference from other compounds during quantitative analysis, 277 nm, the maximum wavelength of the absorption peak close to the visible region, was selected as the wavelength of ultraviolet detection. Figure 2 illustrates the corresponding ultraviolet absorption spectra of antioxidants and their degradation products.

The degradation products of antioxidants (BHT-OH, BHT-COOH, 1310, BHT-CHO, and DBP) contained hydrophilic groups, which had weak interaction with the C18 bonded phase on the chromatographic column and could be easily eluted. To improve the resolution of the degradation products of antioxidants, the proportion of water in the mobile phase was high in the first 19 min.

The solubility of antioxidants (BHT, 3114, 1010, 1330, 1076, and 168) in water was relatively low, which required methanol of a higher concentration to elute antioxidants from the chromatographic column. Antioxidants 1076 and 168 were more hydrophobic and had stronger interaction with the C18 bonded phase on the chromatographic column. In order to shorten the analysis time and improve the peak shape of 1076 and 168, the proportion of methanol was increased to 100% at the later stage of elution.

In order to investigate the effect of mobile phase pH on peak shape and resolution, 0.1%, 0.2%, 0.5%, 1.0%, 1.5%, or 2.0% HAc was added to the deionized water (mobile phase C). When there was no HAc in the deionized water, most of BHT-COOH and 1310 were dissociated into their ions, and the binding capacity of BHT-COOH and 1310 with C18 column was weak, which was washed out earlier and with significant tailing. When HAc was added to the deionized water, the ionization of carboxyl groups of BHT-COOH and 1310 was inhibited. BHT-COOH and 1310 existed in the form of molecules and had a strong ability to bond with C18 column. Therefore, the retention time of BHT-COOH and 1310 was delayed. The acidic environment inhibited the ionization of silanols [25], and more than 99% of silanols were present in molecular state of Si-OH. Adding HAc to the mobile phase could inhibit the ionization of silanol group, prevent the tailing, and improve the resolution. The peaks of antioxidants and their degradation products corresponding to different concentrations of HAc in mobile phase C are shown in Figure 3.

Mobile phase C consisted of HAc and deionized water. The resolution between 1310 and BHT-CHO was increased with the increase of HAc concentration in deionized water. When the concentration of HAc reached 1.0%, the resolution was >2.0. When the concentration of HAc was increased to 1.5%, the resolution changed little. Therefore, 1.0% HAc-water (1:99, v/v) was selected as the final concentration of HAc in the mobile phase C. The resolution of
Figure 2: The UV spectra of antioxidants and their degradation products.

Figure 3: The peaks of antioxidants and their degradation products corresponding to different concentrations of HAc added to mobile phase C peaks: (1) BHT-OH, (2) BHT-COOH, (3) 1310, (4) BHT-CHO, (5) BHT-Q, (6) DBP, (7) BHT, (8) 3114, (9) 1010, (10) 1330, (11) 1076, and (12) 168.
1310 between BHT-CHO corresponding to different concentrations of HAc in mobile phase C is shown in Figure 4.

3.2. System Suitability Testing. Table 3 shows the data of system suitability testing. The resolutions were $>2$; the average theoretical plates were $>40,000$; the capacity factor ranged from 10.72 to 29.35; the tailing factors ranged from 1.00 to 1.07; and the RSD of repeatability was $<2.0\%$. The system suitability testing demonstrated that the HPLC system was adequate for the proposed analytical method. Figure 5 shows the typical HPLC chromatograms of 12 standard solutions.

3.3. Method Validation

3.3.1. LOD, LOQ, and Linearity. The LOD and LOQ were used to evaluate the sensitivity of analytical methods [26]. The LOD is the lowest concentration of analyte that can be detected. Generally, the LOD is the corresponding concentration of analyte when the signal-to-noise ratio is $3:1$. The LOQ is the lowest concentration of analyte that can be quantified. Generally, the LOQ is the corresponding concentration of analyte when the signal-to-noise ratio is $10:1$. The LOD and LOQ of the antioxidants and their degradation products were within the range of $0.011–0.151 \mu g/mL$ and $0.031–0.393 \mu g/mL$, respectively.

Linearity is the degree of proportionality between the measured response value and analyte concentration. The linear correlations of the 12 analytes were good within the concentration range of about $0.1–40.0 \mu g/mL$ and $r>0.999$. The LOD, LOQ, and linearity of antioxidants and their degradation products are presented in Table 4.

3.3.2. Precision. Precision refers to the closeness of agreement between the results obtained from multiple measurements of the same uniform sample under specified conditions. Precision was accessed by intraday precision and interday precision at three different concentration levels of antioxidants ($1 \mu g/mL$, $2 \mu g/mL$, and $5 \mu g/mL$). Precision was evaluated by the RSD of the antioxidant peak area in three different days. The RSD range of intraday and interday precisions of analytes was $0.25–3.17\%$ and $0.47–3.48\%$, respectively. The results showed good precision of the developed analytical method (Table 5).

3.3.3. Accuracy. Accuracy is the degree of closeness between measurement results and the true or reference value [27]. Accuracy was accessed based on the recovery at three different concentration levels of analytes ($0.8 \mu g/mL$, $1 \mu g/mL$, and $1.2 \mu g/mL$). The recoveries were obtained within the range of $80.39\%–104.31\%$, indicating a good accuracy of the developed analytical method. Table 6 lists the accuracy results.

3.3.4. Stability. Stability was assessed by RSD of the analyte peak area in $24\,h$ at three different concentration levels of analytes ($1 \mu g/mL$, $2 \mu g/mL$, and $5 \mu g/mL$). The RSD of the peak area of each analyte was $0.35\%–3.29\%$, indicating that there were no significant changes in each analyte in $24\,h$. Table 7 shows the stability results.

3.4. Analysis of Samples. The samples prepared in Sections 2.3.2 and 2.3.3 were determined by HPLC, and the peak area was substituted into the linear equation to calculate the sample concentration. Five antioxidants (BHT, 1010, 1076, 1330, and 168) and two antioxidant degradation products (1310 and DBP) were detected in packaging materials. In the extractable migration test, only 1310 was detected after the packaged pharmaceutical solution was stored for 0, 3, 6, and 12 months. Figures 6 and 7 illustrate the HPLC chromatograms of extractables in infusion bag and those migrating into the pharmaceutical solution, respectively. Table 8 shows the permitted daily exposure (PDE) of antioxidants and their degradation products, the content of extracts in packaging materials, and the content of extractables that migrated into the pharmaceutical solution.

The PDE refers to the daily average maximum dose of a substance that is allowed to be ingested without any side effects to human body [28]. The maximum daily dose of sodium chloride injection for blood transfusion is about three bags ($250\,mL/bags$). The results showed that the content of 1310 in samples at the time points of 0, 3, 6, and 12 months ranged from $37.44 \mu g/3\,bacs$ to $48.71 \mu g/3\,bacs$, which was lower than the PDE of 1310 ($300 \mu g/day$).
Table 3: The result of system suitability testing (n = 6).

| Analytes | RT (min) | Capacity factor, $K'$ | Resolution, $R$ | Tailing factor | Theoretical number of plate | Repeatability (RSD, %) |
|----------|---------|-----------------------|----------------|---------------|-----------------------------|------------------------|
| BHT-OH   | 11.72   | 10.72                 | 1.07           | 44577         | 1.21                        |
| BHT-COOH | 13.19   | 12.19                 | 6.37           | 46945         | 0.53                        |
| 1310     | 14.12   | 13.12                 | 3.71           | 46948         | 0.83                        |
| BHT-CHO  | 14.68   | 13.68                 | 2.11           | 43604         | 0.57                        |
| BHT-Q    | 18.20   | 17.20                 | 13.06          | 77036         | 0.82                        |
| DBP      | 18.89   | 17.89                 | 2.73           | 94260         | 0.45                        |
| BHT      | 20.83   | 19.83                 | 8.30           | 139300        | 0.40                        |
| 3114     | 25.16   | 24.16                 | 22.21          | 351205        | 0.85                        |
| 1010     | 26.23   | 25.23                 | 5.77           | 261995        | 1.02                        |
| 1330     | 26.98   | 25.98                 | 3.52           | 231756        | 0.62                        |
| 1076     | 29.09   | 28.09                 | 8.54           | 181626        | 0.76                        |
| 168      | 30.35   | 29.35                 | 4.26           | 143418        | 0.43                        |

Table 4: The LOD, LOQ, and linearity.

| Analytes | LOD (μg/mL) | LOQ (μg/mL) | Calibration range (μg/mL) | Linearity | r     |
|----------|-------------|-------------|---------------------------|-----------|-------|
| BHT-OH   | 0.050       | 0.139       | 0.22 ~ 43.46              | $y = 5,930.9470 x + 1,825.7923$ | 0.9996 |
| BHT-COOH | 0.015       | 0.058       | 0.11 ~ 45.28              | $y = 17,708.1278 x - 1,646.5349$ | 1.0000 |
| 1310     | 0.057       | 0.238       | 0.49 ~ 39.14              | $y = 3,920.6502 x - 598.5409$ | 1.0000 |
| BHT-CHO  | 0.011       | 0.031       | 0.10 ~ 41.77              | $y = 33,938.8492 x - 5,298.7072$ | 0.9999 |
| BHT-Q    | 0.151       | 0.393       | 0.48 ~ 38.02              | $y = 2,929.7295 x - 1,549.6531$ | 0.9994 |
| DBP      | 0.042       | 0.116       | 0.19 ~ 38.38              | $y = 7,141.6319 x - 596.6704$ | 1.0000 |
| BHT      | 0.048       | 0.133       | 0.23 ~ 46.80              | $y = 5,549.7995 x - 577.9672$ | 1.0000 |
| 3114     | 0.083       | 0.229       | 0.51 ~ 40.72              | $y = 3,338.2474 x - 524.0559$ | 0.9999 |
| 1010     | 0.054       | 0.175       | 0.20 ~ 40.08              | $y = 3,775.4647 x - 298.1973$ | 1.0000 |
| 1330     | 0.054       | 0.123       | 0.20 ~ 39.82              | $y = 5,433.0830 x - 415.6940$ | 1.0000 |
| 1076     | 0.075       | 0.326       | 0.53 ~ 42.56              | $y = 2,093.7651 x - 303.7811$ | 1.0000 |
| 168      | 0.122       | 0.371       | 0.52 ~ 41.71              | $y = 2,443.9582 x - 555.0495$ | 1.0000 |
Table 5: The intraday and interday precisions \((n = 9)\).

| Analytes | 1 \(\mu\)g/mL | 2 \(\mu\)g/mL | 5 \(\mu\)g/mL | 1 \(\mu\)g/mL | 2 \(\mu\)g/mL | 5 \(\mu\)g/mL |
|----------|-----------------|----------------|----------------|----------------|----------------|----------------|
| BHT-OH   | 1.31            | 0.64           | 2.00           | 1.37           | 1.66           | 1.43           |
| BHT-COOH | 0.99            | 0.82           | 1.76           | 1.24           | 0.96           | 1.31           |
| 1310     | 1.75            | 0.75           | 1.32           | 1.16           | 1.02           | 1.58           |
| BHT-CHO  | 1.46            | 2.31           | 0.51           | 1.26           | 1.67           | 0.47           |
| BHT-Q    | 0.67            | 0.30           | 3.17           | 2.21           | 2.78           | 3.48           |
| DBP      | 1.52            | 0.27           | 2.11           | 1.27           | 1.94           | 1.48           |
| BHT      | 3.08            | 3.03           | 1.91           | 1.80           | 2.41           | 1.32           |
| 3114     | 2.06            | 1.36           | 1.97           | 2.02           | 1.39           | 1.68           |
| 1010     | 3.04            | 1.01           | 2.26           | 1.96           | 1.82           | 1.70           |
| 1330     | 0.25            | 1.07           | 1.87           | 1.64           | 0.66           | 1.27           |
| 1076     | 0.30            | 0.72           | 0.73           | 0.83           | 0.56           | 0.79           |
| 168      | 1.89            | 0.71           | 0.53           | 1.41           | 0.67           | 0.54           |

Table 6: The results of accuracy \((n = 3)\).

| Analytes | 0.8 \(\mu\)g/mL | RSD (%) | Recovery | 1.0 \(\mu\)g/mL | RSD (%) | Recovery | 1.2 \(\mu\)g/mL | RSD (%) | Recovery |
|----------|-----------------|---------|----------|-----------------|---------|----------|-----------------|---------|----------|
| BHT-OH   | 94.84           | 1.46    | 93.99    | 4.24            | 91.54   | 1.94     |
| BHT-COOH | 102.31          | 0.38    | 102.42   | 0.48            | 101.49  | 0.98     |
| 1310     | 89.25           | 1.50    | 94.59    | 0.77            | 92.19   | 1.54     |
| BHT-CHO  | 100.12          | 3.66    | 101.84   | 2.45            | 101.81  | 0.93     |
| BHT-Q    | 88.11           | 1.99    | 87.68    | 2.95            | 80.39   | 3.42     |
| DBP      | 104.31          | 0.70    | 103.68   | 0.90            | 103.87  | 0.92     |
| BHT      | 103.37          | 1.28    | 102.43   | 0.48            | 102.41  | 0.49     |
| 3114     | 100.31          | 2.49    | 95.46    | 3.43            | 96.92   | 3.44     |
| 1010     | 103.65          | 1.12    | 103.00   | 1.13            | 102.59  | 1.88     |
| 1330     | 102.86          | 0.73    | 102.36   | 0.64            | 103.37  | 0.45     |
| 1076     | 95.14           | 2.03    | 98.07    | 1.82            | 96.07   | 3.42     |
| 168      | 98.17           | 0.83    | 98.19    | 0.45            | 99.61   | 4.20     |

Table 7: The stability of antioxidants and their degradation products in 24h \((n = 3)\).

| Analytes | 1 \(\mu\)g/mL | RSD (%) | 5 \(\mu\)g/mL | RSD (%) | 10 \(\mu\)g/mL | RSD (%) |
|----------|----------------|---------|----------------|---------|----------------|---------|
| BHT-OH   | 0.84           | 1.37    | 1.37           | 0.57    |
| BHT-COOH | 2.28           | 1.61    | 1.61           | 0.64    |
| 1310.00  | 1.09           | 3.29    | 3.29           | 1.33    |
| BHT-CHO  | 1.27           | 1.51    | 1.51           | 0.43    |
| BHT-Q    | 1.22           | 1.97    | 1.97           | 1.20    |
| DBP      | 0.98           | 1.34    | 1.34           | 0.35    |
| BHT      | 1.89           | 1.14    | 1.14           | 0.40    |
| 3114     | 0.91           | 1.24    | 1.24           | 0.47    |
| 1010     | 1.62           | 1.60    | 1.60           | 0.64    |
| 1330     | 1.13           | 1.27    | 1.27           | 0.40    |
| 1076     | 1.30           | 2.61    | 2.61           | 1.02    |
| 168      | 1.86           | 2.21    | 2.21           | 0.67    |
Figure 6: The HPLC chromatogram of the infusion bag extract. Peaks: (1) 1310, (2) DBP, (3) BHT, (4) 1010, (5) 1330, (6) 1076, and (7) 168.

Figure 7: The HPLC chromatogram of extractables migrating into sodium chloride solution. Peak: (1) 1310.

Table 8: Contents of antioxidants and their degradation products in samples.

| Analytes | PDE (μg/day) | Packing material extract (μg/bag) | Batch 0 month | Batch 3 months | Batch 6 months | Batch 12 months |
|----------|--------------|----------------------------------|---------------|----------------|---------------|----------------|
|          |              |                                  | Batch 1 | Batch 2 | Batch 3 | Batch 1 | Batch 2 | Batch 3 | Batch 1 | Batch 2 | Batch 3 |
| BHT-OH   | 150          | ND                               | ND       | ND     | ND     | ND       | ND     | ND     | ND       | ND     | ND     |
| BHT-COOH | 150          | ND                               | ND       | ND     | ND     | ND       | ND     | ND     | ND       | ND     | ND     |
| 1310     | 300          | 383.04                           | 46.51    | 39.43  | 41.69  | 38.03    | 37.44  | 43.12  | 38.32    | 40.83  | 48.71  |
| BHT-CHO  | 150          | ND                               | ND       | ND     | ND     | ND       | ND     | ND     | ND       | ND     | ND     |
| BHT-Q    | 150          | ND                               | ND       | ND     | ND     | ND       | ND     | ND     | ND       | ND     | ND     |
| DBP      | 2500         | 2329.29                          | ND       | ND     | ND     | ND       | ND     | ND     | ND       | ND     | ND     |
| BHT      | 150          | 1832.25                          | ND       | ND     | ND     | ND       | ND     | ND     | ND       | ND     | ND     |
### 4. Conclusions

In the present work, five types of antioxidants and two types of antioxidant degradation products were detected in the infusion packaging materials. In the migration experiment, only 1310 was detected in the pharmaceutical solution. The antioxidants were not detected because antioxidants were almost insoluble in water, and they were difficult to migrate into the pharmaceutical solution.

The migrated amount of 1310 in the pharmaceutical solution at time points 0, 3, 6, and 12 months was low and barely changed. The content of 1310 in pharmaceutical solutions did not show a trend of sharp increase. Therefore, it would not cause drug safety risk. At present, most of the studies may not detect the degradation products of antioxidants because they have only developed the method to detect the antioxidants in the pharmaceutical solution. In the present work, 12 antioxidants and their degradation products were scanned by the ultraviolet spectrophotometer within the wavelength range of 190–400 nm, and the optimal detection wavelength for liquid phase conditions was determined to be 277 nm. The HPLC method for the determination of antioxidants (commonly used in the production of infusion bag packaging materials) and their degradation products was established, which could effectively separate 12 analytes in a short time. SPE was used to improve the sensitivity of analytes. The method was verified to be simple and reliable. Collectively, our method could be used not only for detecting antioxidants and their degradation products for infusion solution but also for other formulations.

### Data Availability

All data included in this study are available upon request from the corresponding author.

### Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this work.

### Acknowledgments

This research was financially supported by the Natural Science Foundation of China (No. 81673363).

### References

[1] A. M. Rivera, K. W. Strauss, A. van Zundert, and E. Mortier, “The history of peripheral intravenous catheters: how little plastic tubes revolutionized medicine,” *Acta Anaesthesiologica Belgica*, vol. 56, no. 3, pp. 271–282, 2005.

[2] M. J. Groves, “Some size distributions of particulate contamination found in commercially available intravenous fluids,” *Journal of Pharmacy and Pharmacology*, vol. 18, no. 3, pp. 161–167, 1966.

[3] N. J. Shaw and E. G. Lyall, “Hazards of glass ampoules,” *BMJ*, vol. 291, no. 6506, p. 1390, 1985.

[4] F. Franzetti, B. Borghi, F. Raimondi, and V. D. Rosenthal, “Impact on rates and time to first central vascular-associated bloodstream infection when switching from open to closed intravenous infusion containers in a hospital setting,” *Epidemiology and Infection*, vol. 137, no. 7, pp. 1041–1048, 2009.

[5] M. J. Akers, *Sterile drug products: formulation, packaging, manufacturing and quality*, vol. 208, CRC Press, Boca Raton, FL, USA, 2016.

[6] E. Földes and J. Lohmeijer, “Relationship between chemical structure and performance of primary antioxidants in PBD,” *Polymer Degradation and Stability*, vol. 66, no. 1, pp. 31–39, 1999.

[7] A. Ritter, E. Michel, M. Schmid, and S. Affolter, “Inter-laboratory test on polymers: determination of antioxidants in polyolefins,” *Polymer Testing*, vol. 24, no. 4, pp. 498–506, 2005.

[8] M. Dopico-García, R. Noguerol-Cal, M. Castro-López et al., “Determination of polyolefin additives by reversed-phase liquid chromatography,” *Open Chemistry*, vol. 10, no. 3, pp. 585–610, 2012.

[9] L. Matisová-Rychlá and J. Rychlá, “Chemiluminescence from stabilised polypropylene. The effect of annealing on the induction time of oxidised polypropylene stabilised with Irganox 1010 and Irganox 1076,” *Polymer Degradation and Stability*, vol. 73, no. 3, pp. 393–398, 2001.

[10] A. Rosales-Jasso and N. S. Allen, “Evaluation of some amino-S-triazines and their N-oxyl-derivatives as thermal and UV stabilisers in polypropylene films,” *Polymer Degradation and Stability*, vol. 65, no. 2, pp. 199–206, 1999.

[11] C. Pouech, F. Lafay, L. Wiest, R. Baudot, D. Léonard, and C. Cren-Olivé, “Monitoring the extraction of additives and additive degradation products from polymer packaging into solutions by multi-residue method including solid phase extraction and ultra-high performance liquid chromatography-tandem mass spectrometry analysis,” *Analytical and Bioanalytical Chemistry*, vol. 406, no. 5, pp. 1493–1507, 2014.

[12] B. Marcato, S. Guerra, M. Vianello, and S. Scalia, “Migration of antioxidant additives from various polyolefinic plastics into oleaginous vehicles,” *International Journal of Pharamaceutics*, vol. 257, no. 1-2, pp. 217–225, 2003.
[13] J. Alin and M. Hakkarainen, "Microwave heating causes rapid degradation of antioxidants in polypropylene packaging, leading to greatly increased specific migration to food simulants as shown by ESI-MS and GC-MS," *Journal of Agricultural and Food Chemistry*, vol. 59, no. 10, pp. 5418–5427, 2011.

[14] D. W. Allen, M. R. Clench, A. Crowson, and D. A. Leathard, "Characterisation of solvent-extractable transformation products of high molecular weight hindered phenols in polypropylene subjected to ionising radiation in air or to thermal ageing," *Polymer Degradation and Stability*, vol. 39, no. 3, pp. 293–297, 1993.

[15] J. F. Schabron and L. E. Fenska, "Determination of BHT, Irganox 1076, and Irganox 1010 antioxidant additives in polyethylene by high performance liquid chromatography," *Analytical Chemistry*, vol. 52, no. 9, pp. 1411–1415, 1980.

[16] C. Moreta and M.-T. Tena, "Determination of plastic additives in packaging by liquid chromatography coupled to high resolution mass spectrometry," *Journal of Chromatography A*, vol. 1414, pp. 77–87, 2015.

[17] A. De Paeppe, B. Erlandsson, J. Östelius, U. Gasslander, and A. Arbin, "An alternative method for determination of additives in polypropylene using supercritical fluid extraction and enhanced solvent extraction," *Journal of Liquid Chromatography & Related Technologies*, vol. 29, no. 11, pp. 1541–1559, 2006.

[18] POLYOLEFINS, *European Pharmacopoeia*, POLYOLEFINS, Strasbourg, France, 2013.

[19] R. Zhang, C. Li, Y. Li, X. Cui, and L. Q. Ma, "Determination of 2,6-di-tert-butyl-hydroxytoluene and its transformation products in indoor dust and sediment by gas chromatography-mass spectrometry coupled with precolumn derivatization," *Science of the Total Environment*, vol. 619-620, pp. 552–558, 2018.

[20] L. Burman, A.-C. Albertsson, and A. Höglund, "Solid-phase microextraction for qualitative and quantitative determination of migrated degradation products of antioxidants in an organic aqueous solution," *Journal of Chromatography A*, vol. 1080, no. 2, pp. 107–116, 2005.

[21] H. Zweifel, *Stabilization of Polymeric Materials*, p. 219, Springer Science & Business Media, Berlin, Germany, 2012.

[22] K. Schwetlick, J. Pioncek, A. Winkler, U. Hähner, H. Kroschwitz, and W. D. Habicher, "Organophosphorus antioxidants: Part X—mechanism of antioxidant action of aryl phosphites and phosphonites at higher temperatures," *Polymer Degradation and Stability*, vol. 31, no. 2, pp. 219–228, 1991.

[23] 2017 USP, General Chapter USP<621>, Chromatography, Physical Tests, United States Pharmacopeia, First Supplement to USP 40-NF 35.

[24] B. Rivero and I. Garibay, "Development and validation of a stability-indicating HPLC method for the quantification of α-mangostin in dietary supplements," *Natural Product Communications*, vol. 14, no. 7, Article ID 1934578X19863948, 2019.

[25] B. Law, *Pharmaceuticals Basic Drugs: Liquid Chromatography*, Academic Press, Cambridge, MA, USA, pp. 3701–3708, 2000.

[26] M. Stauffer, *Calibration and Validation of Analytical Methods: A Sampling of Current Approaches*, BoD-Books on Demand, Norderstedt, Germany, 2018.

[27] A. Menditto, M. Patriarca, and B. Magnusson, "Understanding the meaning of accuracy, trueness and precision," *Accreditation and Quality Assurance*, vol. 12, no. 1, pp. 45–47, 2007.

[28] European Medicine Agency, *Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities*, European Commission, Enterprise and Industry, Brussels, Belgium, 2014.